Pharmaceutical Market Access Act of 2007

Bill: 110-s-251
Sponsor: Sen. Vitter, David [R-LA]
Introduced: 2007-01-10 in the Senate
Policy area: Health
Subjects: Administrative fees
Administrative procedure
Administrative remedies
Africa (Sub-Saharan)
Australia
Austria
Belgium
Business records
Canada
Civil actions and liability
Commerce
Congress
Congressional reporting requirements
Consumer education
Consumer protection
Damages
Denmark
Department of Health and Human Services
Drug approvals
Drug industry
Drugs
East Asia
Economics and Public Finance
Electronic government information
Europe
Evidence (Law)
Federal Trade Commission
Federal-state relations
Finland
Foreign Trade and International Finance
France
Germany
Government Operations and Politics
Government paperwork
Government publicity
Governmental investigations
Greece
Iceland
Identification devices
Import restrictions
Imports
Independent regulatory commissions
Injunctions
Intellectual property
Internet
Ireland
Israel
Italy
Japan
Labeling
Law
Licenses
Liechtenstein
Limitation of actions
Luxembourg
Netherlands
New Zealand
Norway
Oceania
Packaging
Parties to actions
Patent infringement
Patents
Pharmacies
Pharmacists
Portugal
Prescription pricing
Price discrimination
Product counterfeiting
Product safety
Punitive damages
Restrictive trade practices
Science, Technology, Communications
South Africa
Spain
Sweden
Switzerland
Telephone
United Kingdom
Web sites
Wholesale trade

Summary:
action_date: 2007-01-10
text: 
Pharmaceutical Market Access Act of 2007 - Amends the Federal Food, Drug, and Cosmetic Act to require the Secretary of Health and Human Services to promulgate regulations permitting pharmacists, pharmacies, and wholesalers to import qualifying drugs from certain countries into the United States.
 
Sets forth registration requirements for exporters.
 
Requires the Secretary to: (1) educate consumers with regard to the availability of qualifying drugs for import for personal use; (2) inspect the facilities and records of importers and registered exporters to ensure compliance with this Act; and (3) establish a registration fee program to collect an annual fee from registered exporters.
 
Deems a prescription drug to be misbranded unless the packaging of such drug complies with the requirements for counterfeit-resistant technologies.
 
Prohibits: (1) failing to register in accordance with this Act; and (2) importing or offering to import a prescription drug in violation of a suspension order.
 
Declares that selling or importing a patented drug in the United States that was first sold abroad by or under authority of the owner or licensee of the patent is not patent infringement.
 
Prohibits drug manufacturers from discriminating against a person that engages in the importation of a prescription drug, including by charging higher prices or denying supplies of the drug.
 
Allows the Secretary to suspend or terminate the registration of an exporter for failing to maintain substantial compliance with all registration conditions.


Legislative actions:
action_date: 2007-01-10
text: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
action_date: 2007-01-10
text: Introduced in Senate